Investor Ideas #Potcasts, #Cannabis News and Stocks on
the Move: (CSE: $DIXI_U.C), (CSE: $SNN.C), (TSX: $ACB.TO) (NYSE: $ACB),
(TSX: $APHA.TO) (NYSE: $APHA), (CSE: $SOL.C)
Delta, Kelowna, BC –April
5th, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insights from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/04051DIXI-SNN-ACB-APHA-SOL.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another Investorideas.com “potcast” looking at
cannabis news, stocks to watch as well as insights from experts and industry
leaders.
Today
we are looking at announcements from Dixie Brands Inc, Sunniva Inc, Aurora Cannabis Inc. Aphria Inc. and SOL
Global Investments Corp.
Dixie Brands Inc. (CSE: DIXI.U), (OTC: DXBRF), one of the
cannabis industry's leading consumer packaged goods (CPG) companies, has announced plans to
introduce a new confectionary product called Dixie Bursts™. The pulled taffy
chews will be sold in assorted packages containing Blue Raspberry, Mango and
Strawberry flavors. Each individually-wrapped Burst will contain 10 milligrams
of THC.
"Dixie has been crafting quality
infused-cannabis products for nearly a decade and is constantly seeking new
ways to satisfy the evolving needs of our consumers who love to explore new
flavors and formats," said Andrew Floor, Dixie's Vice President of
Marketing. "We've had a phenomenal reaction to our latest innovation,
Dixie Bursts, a hand-pulled taffy which is absolutely bursting with flavor and
has a softer texture than the few comparable products in the market
today."
Edibles are gaining popularity in
jurisdictions where cannabis use is permitted, with sales growth rates
outpacing those of dried flower. For example, according to BDS Analytics data
for January 2019 in Colorado, one of the most mature cannabis markets in the
U.S., sales of both flower and pre-rolled joints declined from one year earlier
and now represent less than half of total sales. Sales of ingestibles in the state increased
by 17% over the same period, with the candy sub-category growing by 25%.
Sunniva Inc. (CSE:
SNN) (OTCQB:
SNNVF), a North American provider of cannabis
products and services, announced
preliminary revenue of $14.0 million for the three month period ended March 31,
2019. This represents a 169% increase
over the $5.2 million in revenue generated in the comparative three-month
period from 2018.
In California, Sunniva began selling
cannabis products in the first three months of 2019 through its wholly-owned
subsidiary, CP Logistics, LLC with preliminary revenue of $10.0 million (USD
$7.5 million). Revenue was comprised of product sales from premium flower, vape
cartridges and concentrates. In March, Sunniva unveiled its first three in-house
brands, Sun Fire, KYNDNESS and Herbella, and announced that additional super
premium brands will be launched in conjunction with production from the 325,000
sq. ft. purpose-built greenhouse under construction in Cathedral City,
California.
The Company's other wholly owned
subsidiaries, Full-Scale Distributors, LLC and Natural Health Services Ltd.,
contributed first quarter 2019 revenue of $2.3 million and $1.7 million,
respectively.
"In California, we now have the
strategic pillars in place to ensure scalability and growth for our newly
announced brands and we are very proud of our entire team for the execution and
delivery of a very strong first quarter," said Dr. Anthony Holler, CEO of
Sunniva. "Our $14.0 million in revenue during the first quarter is close
to the total revenue generated by Sunniva in all of 2018. With strong
leadership and operating assets producing premium cannabis products, supported
by our recent distribution company acquisition, we continue to demonstrate our
ability to achieve significant revenue growth and secure shelf space for our
Sunniva brands throughout the state."
Aurora Cannabis Inc. (TSX:
ACB) (NYSE:
ACB), announced
today that the Company has been selected by
the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal
Institute for Drugs and Medical Devices) as one of three winners in the public
tender to cultivate and distribute medical cannabis in Germany. The contract
will be formalized at the earliest on April 17, 2019, pending the outcome of an
appeal procedure on which a ruling is anticipated by April 10, 2019.
The tender saw 79 companies
participating, with the winners able to
establish production in Germany upon the completion of the contract associated
with the tender. The selection process was based on the submission of a concept
for domestic cannabis production, delivery and pricing. Aurora's concept,
judged on criteria such as facility design, quality, security and logistics,
received the highest ranking out of all concepts submitted, validating the
Company's leadership in integrated cultivation, production and delivery.
The Company was awarded the maximum
number of 5 of the 13 lots in the tender over a period of four years with a
minimum supply of 4000kg total. The cannabis produced will be sold to the
German government and supplied to wholesalers for distribution to pharmacies.
Aphria Inc. (TSX:
APHA) (NYSE:
APHA is
also entering the German market having announced that
its German subsidiary Aphria Deutschland GmbH has been selected by the German
Federal Institute for Drugs and Medical Devices ("BfArM") to receive
a license for the domestic cultivation of medical cannabis. The provisional
decision announced by BfArM is subject to a mandatory 10-day standstill period
for public contracts, which permits unsuccessful bidders to challenge the
decision before the final contract is signed. BfArM's decision would grant
Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200
kg.
"Aphria is proud to have been
selected as a successful applicant in the German tender process, a testament to
our high production quality standards," said Hendrik Knopp, Managing
Director of Aphria Germany. "The decision from BfArM is a validation of
our strategic approach to supporting the German medical cannabis market,
including with high-quality, domestic production to secure vital supply for
patients. We are very pleased with our continued business momentum in
Germany."
SOL Global Investments Corp. (CSE:SOL) (OTCQB:SOLCF), announced that it intends
to spin off its wholly-owned subsidiary, Scythian Biosciences Inc.
("SBI"), into an independent, publicly-traded company. Upon closing
of the Spin-off, which is expected to occur on or before September 30, 2019,
SOL shareholders will own shares of both companies.
In connection with the Spin-off, SBI will
be renamed "Impact Biosciences Corp" ("Impact") and will
continue to pursue a drug development in the United States for the treatment of
concussions and traumatic brain injury with its proprietary Cannabinoid
combination drug candidate, which is being developed under contract with the
University of Miami. Impact's mission is to become the first accepted drug
regimen for concussive treatment. Impact has a collaboration with the
University of Miami and its world-renowned neuroscientific team to conduct
pre-clinical and clinical trials of its drug regimen.
Impact's Traumatic Brain Injury (TBI)
Combination Therapy is currently in the pre-clinical research phase and is
undergoing animal testing. Upon completion of this pre-clinical phase and
applicable IND enabling studies, Impact will prepare and file an
investigational new drug ("IND") application with the FDA, which, if
granted, would permit Impact to begin human testing. Impact has applied for two
patents related to its TBI treatment strategy, involving the combination of
multiple chemical pathways into a therapeutic regimen targeted at reducing
post-injury inflammation and inhibiting the resultant gliosis and the immune
cascade. Impact has found a unique way to apply several pre-existing drugs in a
way not previously done to target these processes.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
Get the cannabis/hemp stock directory as an Investor ideas member , plus
get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the
Move. Learn more https://www.investorideas.com/membership/
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher
of third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated for
news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers.
Learn more about Investor ideas podcast
and news publication services and costs https://www.investorideas.com/News-Upload/
Global investors must adhere to
regulations of each country.
Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
